Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-05T16:28:39.128Z Has data issue: false hasContentIssue false
  • English
  • Français

Hormone replacement therapy for osteoporosis: clinical and pathophysiological aspects

Published online by Cambridge University Press:  02 March 2009

JE Compston
JE Compston*
Affiliation:
Department of Medicine, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge, UK
*
JE Compston, Department of Medicine, University of Cambridge Clinical School, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK
Get access Rights & Permissions [Opens in a new window]

Extract

The pathogenetic role of oestrogen deficiency in osteoporosis was first postulated by Fuller Albright in 1941 and has subsequently become well established. Hormone replacement therapy prevents menopausal bone loss and is the only treatment which has convincingly been shown to reduce fracture risk at both the spine and hip. The mechanisms by which oestrogens affect bone, however, are poorly understood and many aspects of treatment remain ill-defined, in particular with respect to the duration of therapy and its long-term risks and benefits.

Type
Articles
Information
Reproductive Medicine Review , Volume 3 , Issue 3 , October 1994 , pp. 209 - 224
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Albright, F, Smith, PH, Richardson, AM. Postmenopausal osteoporosis. JAMA 1941; 116: 2465–74.CrossRefGoogle Scholar
2Compston, JE. HRT and osteoporosis. Br Med Bull 1992; 48: 309–44.CrossRefGoogle ScholarPubMed
3Melton, LJ, Chrischilles, EA, Cooper, C, Lane, AW, Riggs, BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005–1010.CrossRefGoogle ScholarPubMed
4Kanis, JA, Pitt, FA. Epidemiology of osteoporosis. Bone 1992; 13 (suppl 1): 7–15.CrossRefGoogle ScholarPubMed
5Schaadt, O, Bohr, H. Different trends of age-related diminution of bone mineral content in the lumbar spine, femoral neck and femoral shaft in women. Calcif Tissue Int 1988; 42: 71–76.CrossRefGoogle ScholarPubMed
6Riggs, BL, Wahner, HW, Melton, LJ, Richelson, LS, Judd, HL, Offord, KP. Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest 1986; 77: 1487–91.CrossRefGoogle ScholarPubMed
7Rodin, A, Murby, B, Smith, MA et al. Premenopausal bone loss in the lumbar spine and neck of femur: a study of 225 Caucasian women. Bone 1990; 11: 1–5.CrossRefGoogle ScholarPubMed
8Cann, CE, Genant, HK, Kolbo, FO, Ettinger, B. Quantitative computed tomography for prediction of vertebral fracture risk. Bone 1985; 6: 1–7.CrossRefGoogle ScholarPubMed
9Hui, SL, Slemenda, CW, Johnston, CC, Appledorn, CR. Effects of age and menopause on vertebral bone density. Bone Miner 1987; 2:141–46.Google ScholarPubMed
10Elders, PJM, Netelenbos, JC, Lips, P, van Ginkel, FC, van der Stelt, PF. Accelerated vertebral bone loss in relation to the menopause: a cross-sectional study on lumbar bone density in 286 women of 46–55 years of age. Bone Miner 1988; 5: 11–19.CrossRefGoogle Scholar
11Nilas, L, Christiansen, C. Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 1988; 18: 529–34.CrossRefGoogle ScholarPubMed
12Genant, HK, Cann, CE, Ettinger, B, Gilbert, SG. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982; 97: 699–705.CrossRefGoogle ScholarPubMed
13Mazess, RB, On ageing and bone loss. Clin Orthop 1982; 165: 239–52.CrossRefGoogle Scholar
14Riggs, BL, Wahner, HW, Dunn, WL, Mazess, RB, Offord, KP, Melton, LJ. Differential changes in bone mineral density of the appendicular skeleton with ageing: relationship to spinal osteoporosis. J Clin Invest 1987; 80: 258–62.Google Scholar
15Christiansen, C, Riis, BJ, Rodbro, P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987; i: 1105–108.CrossRefGoogle Scholar
16Hui, SL, Slemenda, CW, Johnston, CC. The contribution of bone loss to postmenopausal osteoporosis. Osteoporos Int 1990; 1: 30–34.CrossRefGoogle ScholarPubMed
17Rigotti, NA, Nussbaum, SR, Herzog, DB, Neer, RM. Osteoporosis in women with anorexia nervosa. N Engl J Med 1984; 311: 1601–606.CrossRefGoogle ScholarPubMed
18Shore, RM, Chesney, RW, Mazess, RB, Rose, PG, Bergman, GJ. Skeletal demineralisation in Turner's syndrome. Calcif Tissue Int 1982; 34: 519–22.CrossRefGoogle ScholarPubMed
19Klibanski, A, Greenspan, SL. Increase in bone mass after treatment of hyperprolactinaemic amenorrhoea. N Engl J Med 1986; 315: 542–46.CrossRefGoogle Scholar
20Drinkwater, BL, Nilson, K, Chestnut, CH, Bremmer, WJ, Shainholtz, S, Southworth, MB. Bone mineral content of amenorrhoeic and eumenorrhoeic athletes. N Engl J Med 1984; 311: 277–81.CrossRefGoogle Scholar
21Matta, WH, Shaw, RW, Hesp, R, Evans, R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol (Oxf) 1988; 29: 45–51.CrossRefGoogle ScholarPubMed
22Alderman, BW, Weiss, NS, Daling, JR, Ure, CL, Ballard, JH. Reproductive history and postmenopausal risk of hip and forearm fracture. Am J Epidemiol 1986; 124: 262–67.CrossRefGoogle ScholarPubMed
23Murphy, S, Khaw, K-T, Compston, JE. Lack of relationship between hip and spine bone mineral density and oral contraceptive use. Eur J Clin Invest 1993; 23: 108–11.CrossRefGoogle ScholarPubMed
24Lindsay, R, Hart, DM, Forrest, C, Baird, C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 1980; ii: 1151–53.CrossRefGoogle Scholar
25Nactigall, LE, Nachtigall, RH, Nachtigall, RD, Beckman, EM. Estrogen replacement therapy 1: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 53: 277–81.Google Scholar
26Christiansen, C, Christensen, MS, McNair, PL, Hagen, C, Stocklund, KE, Transbol, I. Prevention of early postmenopausal bone loss: conducted 2-year study in 315 normal females. Eur J Clin Invest 1980; 10: 273–79.CrossRefGoogle Scholar
27Ettinger, B, Genant, HK, Cann, CE. Long-term oestrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24.CrossRefGoogle ScholarPubMed
28Christiansen, C, Riis, BJ. 17β-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990; 71: 836–41.CrossRefGoogle ScholarPubMed
29Stevenson, JC, Cust, MP, Gangar, KF, Hillard, TC, Lees, B, Whitehead, MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 335: 265–69.CrossRefGoogle Scholar
30Gallagher, JC, Kable, WT, Goldgar, D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90: 171–78.CrossRefGoogle Scholar
31Hutchinson, A, Polansky, SM, Feinstein, AR. Post-menopausal estrogens protect against fractures of the hip and distal radius: a case control study. Lancet 1979; ii: 705–709.CrossRefGoogle Scholar
32Weiss, NS, Ure, CL, Ballard, JH, Williams, AR, Daling, JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens. N Engl J Med 1980; 303: 1195–98.CrossRefGoogle Scholar
33Paganini-Hill, A, Ross, RK, Gerkins, VR, Henderson, BE, Arthur, M, Mack, TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1981; 95: 28–31.CrossRefGoogle ScholarPubMed
34Kiel, DP, Felson, DT, Anderson, JJ, Wilson, PWF, Moskowitz, MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987; 317: 1169–74.CrossRefGoogle ScholarPubMed
35Naessen, T, Persson, I, Adami, H-O, Bergstrom, R, Bergkvist, L. Hormone replacement therapy and risk for first hip fracture. Ann Intern Med 1990; 113: 95–103.CrossRefGoogle ScholarPubMed
36Riggs, BL, Seeman, E, Hodgson, SF, Taves, DR, O'Fallon, WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. N Engl J Med 1982; 306: 446–50.CrossRefGoogle ScholarPubMed
37Lindsay, R, Hart, DM, MacLean, A, Clark, AC, Kraszewski, A, Garwood, J. Bone response to termination of oestrogen treatment. Lancet 1978; i: 1325–27.CrossRefGoogle Scholar
38Christiansen, C, Christensen, MS, Transbol, I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen therapy. Lancet 1981; i: 459–61.CrossRefGoogle Scholar
39Felson, DT, Zhang, Y, Hannan, MT, Kiel, DP, Wilson, PWF, Anderson, JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 1141–46.CrossRefGoogle Scholar
40Hayes, WC, Gerhart, TN. Biomechanics of bone: applications for assessment of bone strength. In: Peck, WA ed. Bone and mineral research Volume 3, Amsterdam: Elsevier, 1985: 259–94.Google Scholar
41Wasnich, RD, Ross, PD, Heilbrun, LK, Vogel, JM. Prediction of postmenopausal fracture risk with bone mineral measurements. Am J Obstet Gynecol 1985; 153: 745–51.CrossRefGoogle ScholarPubMed
42Hui, SL, Slemenda, CW, Johnston, CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81: 1804–809.CrossRefGoogle ScholarPubMed
43Gärdsell, P, Johnell, O, Nilsson, B. Predicting fractures in women by using forearm bone densitometry. Calcif Tissue Int 1989; 44: 235–42.CrossRefGoogle ScholarPubMed
44Cummings, SR, Black, DM, Nevitt, MC et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341: 72–75.CrossRefGoogle ScholarPubMed
45Faulkner, KG, Cummings, SR, Glüer, CC, Palermo, L, Black, D, Genant, HK. Simple measurement of femoral geometry predicts hip fracture. J Bone Miner Res 1993; 8: 1211–17.CrossRefGoogle ScholarPubMed
46Ross, PD, Davis, JW, Epstein, RS, Wasnich, RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114: 919–23.CrossRefGoogle ScholarPubMed
47Slemenda, CW, Hui, SL, Longcope, C, Wellman, H, Johnston, CC. Predictors of bone mass in perimenopausal women. A prospective study of clinical data using photon absorptiometry. Ann Intern Med 1990; 112: 96–101.CrossRefGoogle ScholarPubMed
48Grady, D, Rubin, SM, Petitti, DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37.CrossRefGoogle ScholarPubMed
49Bergkvist, L, Adami, HO, Persson, I, Hoover, R, Schairer, C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293–97.CrossRefGoogle ScholarPubMed
50Colditz, GA, Stampfer, MJ, Willett, WC, Hennekens, CH, Rosner, B, Speizer, FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990; 264: 2648–53.CrossRefGoogle ScholarPubMed
51Bush, TL, Barrett-Connor, E, Cowan, LD et al. Cardiovascular mortality and non-contraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study. Circulation 1987; 75: 1102–109.CrossRefGoogle Scholar
52Barrett-Connor, E, Bush, TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861–67.CrossRefGoogle ScholarPubMed
53Wolf, PH, Madans, JH, Finucane, FF, Higgins, M, Kleinman, JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164: 489–94.CrossRefGoogle ScholarPubMed
54Nabulsi, AA, Folsom, AR, White, A et al. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069–75.CrossRefGoogle ScholarPubMed
55Falkeborn, M, Persson, I, Adami, H-O et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821–28.CrossRefGoogle ScholarPubMed
56Falkeborn, M, Persson, I, Terént, A, Adami, H-O, Lithell, H, Bergström, R. Hormone replacement therapy and the risk of stroke. Arch Intern Med 1993; 153: 1201–209.CrossRefGoogle ScholarPubMed
57Parfitt, AM. The cellular basis of bone remodelling. The quantum concept re-examined in light of recent advances in cell biology of bone. Calcif Tissue Int 1984; 36 (suppl): S37–S45.CrossRefGoogle Scholar
58Lanyon, LE. The success and failure of the adaptive response to functional load-bearing in averting vertebral fracture. Bone 1992; 13 (suppl 2): S17–S21.CrossRefGoogle Scholar
59Scheven, BAA, Visser, JWM, Nijweide, PJ. In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 1986; 321: 79–81.CrossRefGoogle ScholarPubMed
60Horton, MA, Davies, J. Perspectives: adhesion receptors in bone. J Bone Miner Res 1989; 4: 803–807.CrossRefGoogle ScholarPubMed
61Baron, R, Vignery, A, Horowitz, M. Lymphocytes, macrophages and the regulation of bone remodelling. In: Peck, WA ed. Bone and mineral research, Volume 2. Amsterdam: Elsevier, 1984: 175–245.Google Scholar
62Owen, ME. Lineage of osteogenic cells and their relationship to the stromal system. In: Peck, WA ed. Bone and mineral research, Volume 3. Amsterdam: Elsevier, 1985: 1–25.Google Scholar
63Compston, JE, Croucher, PI. Histomorphometric assessment of trabecular bone remodelling in osteoporosis. Bone Miner 1991; 14: 91–102.CrossRefGoogle ScholarPubMed
64Frost, HM. Tetracycline-based histological analysis of bone remodelling. Calcif Tissue Int 1969; 3: 211–37.CrossRefGoogle Scholar
65Eriksen, EF. Normal and pathological remodelling of human trabecular bone: three dimensional reconstruction of the remodelling sequence in normals and in metabolic bone disease. Endocr Rev 1986; 7: 379–408.CrossRefGoogle ScholarPubMed
66Garrahan, NJ, Croucher, PI, Compston, JE. A computerised technique for the quantitative assessment of resorption cavities in trabecular bone. Bone 1990; 11: 241–46.CrossRefGoogle ScholarPubMed
67Cohen-Solal, ME, Shih, M-S, Lundy, MW, Parfitt, AM. A new method for measuring cancellous bone erosion depth: application to the cellular mechanisms of bone loss in postmenopausal osteoporosis. J Bone Miner Res 1991; 6:1331–38.CrossRefGoogle Scholar
68Russell, RGG. The physiological regulation of bone metabolism. In: Ring, EFJ, Evans, WD, Dixon, AS eds. Osteoporosis and bone mineral measurement. York, England: IPSM, 1989: 147–76.Google Scholar
69MacDonald, BR, Gowen, M. Cytokines and bone. Br J Rheumatol 1992; 31: 149–55.CrossRefGoogle ScholarPubMed
70Gallagher, JC, Godgar, D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 1990; 113: 649–55.CrossRefGoogle ScholarPubMed
71Lukert, BP, Raisz, LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352–64.CrossRefGoogle Scholar
72Reeve, J, Meunier, PJ, Parsons, JA. Anabolic effect of human parathyroid fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1980; 280: 1340–44.CrossRefGoogle ScholarPubMed
73O'Halloran, DJ, Tsatsoulis, A, Whitehouse, RW, Holmes, SJ, Adams, JE, Shalet, SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated growth hormone deficiency. J Clin Endocrinol Metab 1993; 76: 1344–48.Google Scholar
74Allain, TJ, McGregor, AM. Thyroid hormones and bone. J Endocrinol 1993; 139: 9–18.CrossRefGoogle ScholarPubMed
75Felix, R, Cecchini, MG, Fleisch, H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 1990; 127: 2592–94.CrossRefGoogle ScholarPubMed
76Heaney, RP, Recker, RR, Saville, PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978; 92: 953–63.Google ScholarPubMed
77Nordin, BEC, Need, AG, Morris, HA, Horowitz, M, Robertson, WG. Evidence for a renal calcium leak in postmenopausal women. J Clin Endocrinol Metab 1991; 72: 401–407.CrossRefGoogle ScholarPubMed
78Stepan, JJ, Pospichal, J, Presl, J, Pacovsky, V. Bone loss and biochemical indices of bone remodelling in surgically induced postmenopausal women. Bone 1987; 8: 279–84.CrossRefGoogle ScholarPubMed
79Wronski, TJ, Lowry, PL, Walsh, CC, Ignazewski, LA. Skeletal alterations in ovariectomised rats. Calcif Tissue Int 1985; 37: 324–28.CrossRefGoogle Scholar
80Vedi, S, Compston, JE, Webb, A, Tighe, JR. Histomorphometric analysis of dynamic parameters of trabecular bone formation in the iliac crest of normal British subjects. Metab Bone Dis Relat Res 1983; 5: 69–74.CrossRefGoogle ScholarPubMed
81Eastell, R, Delmas, PD, Hodgson, SF, Eriksen, EF, Mann, KG, Riggs, BL. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 1988; 67: 741–48.CrossRefGoogle ScholarPubMed
82Whyte, PM, Bergfeld, MA, Murphy, WA, Avioli, LV, Teitelbaum, SL. Post-menopausal osteoporosis. A heterogenous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med 1982; 72: 192–202.Google ScholarPubMed
83Meunier, PJ, Courpron, P, Edouard, C et al. Bone histomorphometry in osteoporotic states. In: Barzel, US ed. Osteoporosis, Volume II. New York: Grune and Stratton, 1979: 27–47.Google Scholar
84Eriksen, EF, Hodgson, SF, Eastell, R, Cedel, SL, O'Fallon, WM, Riggs, BL. Cancellous bone remodelling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption and bone loss at tissue and cellular levels. J Bone Miner Res 1990; 5: 311–19.CrossRefGoogle ScholarPubMed
85Darby, AJ, Meunier, PJ. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981; 33: 199–204.CrossRefGoogle ScholarPubMed
86Garcia-Carasco, M, De Vernejoul, MC, Sterkers, Y, Morieux, C, Kuntz, D, Miravet, L. Decreased bone formation in osteoporotic patients compared to age-matched controls. Calcif Tissue Int 1989; 44: 173–75.CrossRefGoogle ScholarPubMed
87Arlot, M, Edouard, , Meunier, PJ, Neer, RM, Reeve, J. Impaired osteoblast function in osteoporosis: comparison between calcium balance and dynamic histomorphometry. Br Med J 1984; 289: 517–20.CrossRefGoogle ScholarPubMed
88Steiniche, T, Hasling, C, Charles, P, Eriksen, EF, Mosekilde, L, Melsen, F. A randomised study on the effects of oestrogen-gestagen or high dose oral calcium on trabecular bone remodelling in postmenopausal osteoporosis. Bone 1989; 10: 313–20.CrossRefGoogle ScholarPubMed
89Eriksen, EF, Colvard, DS, Berg, NJ et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988; 241: 84–86.CrossRefGoogle ScholarPubMed
90Komm, BS, Terpening, CM, Benz, DJ et al. Estrogen binding, receptor mRNA and biologic response in osteoblast-like osteosarcoma cells. Science 1988; 241: 81–85.CrossRefGoogle ScholarPubMed
91Pacifici, R, Brown, C, Puscheck, E et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 1991; 88: 5134–38.CrossRefGoogle ScholarPubMed
92Ralston, SH, Russell, RGG, Gowen, M. Estrogen inhibits release of tumour necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res 1990; 5: 983–88.CrossRefGoogle ScholarPubMed
93Jilka, RL, Hangoc, G, Girasole, G et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88–91.CrossRefGoogle ScholarPubMed
94Gray, TK, Mohan, S, Linkhart, TA, Baylink, DJ. Estradiol stimulates in vitro the secretion of insulin-like growth factors by the clonal osteoblastic cell-line, UMR 106. Biochem Biophys Res Commun 1989; 158: 407–12.CrossRefGoogle Scholar
95Ernst, M, Heath, JK, Rodan, GA. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-1, and parathyroid hormone-stimulating adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 1989; 125: 825–33.CrossRefGoogle Scholar
96Compston, JE, Mellish, RWE, Croucher, PI, Newcombe, R, Garrahan, NJ. Structural mechanisms of trabecular bone loss in man. Bone Miner 1989; 6: 339–50.CrossRefGoogle ScholarPubMed
97Parfitt, AM, Mathews, CHE, Villanueva, AR, Kleerekoper, M, Frame, B, Rao, DS. Relationship between surface, volume and thickness of iliac trabecular bone in ageing and in osteoporosis. J Clin Invest 1983; 72: 1396–409.CrossRefGoogle ScholarPubMed
98Mellish, RWE, Garrahan, NJ, Compston, JE. Age-related changes in trabecular width and spacing in human iliac crest biopsies. Bone Miner 1989; 6: 331–38.CrossRefGoogle ScholarPubMed
99Croucher, PI, Garrahan, NJ, Compston, JE. Structural mechanisms of trabecular bone loss in primary osteoporosis: specific disease mechanism or early ageing? Bone Miner 1994; 25: 111–21.CrossRefGoogle ScholarPubMed
100Aitken, JM. Relationship between mortality after femoral neck fracture and osteoporosis. In: Christiansen, C, Johansen, JS, Riis, BJ eds. Osteoporosis 1987 Copenhagen: Osteopress ApS, 1987; 45–48.Google Scholar
101Browner, WS, Seely, DG, Vogt, TM, Cummings, SR. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991; 338: 355–58.CrossRefGoogle ScholarPubMed
102Parvizi, ST, Minne, HW, Bauss, F, Ziegler, R. Antioestrogens treatment produces loss of bone mass as a side-effect in the rat. Acta Endocrinol (Copenh) 1985; 108: 168–71.Google Scholar
103Turner, RT, Wakley, GK, Hannon, KS, Bell, NH. Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats. J Bone Miner Res 1987; 5: 449–56.CrossRefGoogle Scholar
104Gotfredson, A, Christiansen, C, Palshof, T. The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer 1984; 53: 853–57.3.0.CO;2-M>CrossRefGoogle Scholar
105Love, RR, Mazess, RB, Barden, HS et al. Effects of tamoxifen on bone mineral density in postmenopausl women with breast cancer. N Engl J Med 1992; 326: 852–56.CrossRefGoogle Scholar
106Ward, RL, Morgan, G, Dalley, D, Kelly, PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993; 22: 87–94.CrossRefGoogle ScholarPubMed
107Neal, AJ, Evans, K, Hoskin, PJ. Does long-term administration of tamoxifen affect bone mineral density? Eur J Cancer 1993; 29A: 1971–73.CrossRefGoogle ScholarPubMed
108Wright, CDP, Mansell, RE, Gazet, J-C, Compston, JE. Effect of long term tamoxifen treatment on bone turnover in women with breast cancer. Br Med J 1993; 306: 429–30.CrossRefGoogle Scholar
109Wright, CDP, Garrahan, NJ, Stanton, M, Gazet, J-C, Mansell, RE, Compston, JE. Effect of long-term tamoxifen therapy on cancellous bone remodelling and structure in women with breast cancer. J Bone Miner Res 1994; 9: 153–59.CrossRefGoogle Scholar
110Johansen, JS, Riis, BJ, Hassager, C, Moen, M, Jacobson, J, Christiansen, C. The effect of a gonadotrophin-releasing hormone agonist (naferelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701–706.CrossRefGoogle Scholar
111Dawood, MY, Lewis, V, Ramos, J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotrophin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21–26.CrossRefGoogle ScholarPubMed
112Jacobson, JB. Effects of naferelin on bone density. Am J Obstet Gynecol 1990; 162: 589–92.CrossRefGoogle Scholar
113Whitehouse, RW, Adams, JE, Bancroft, K, Vaughan-Williams, CA, Elstein, M. The effects of naferelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin Endocrinol 1990; 33: 365–73.CrossRefGoogle Scholar
114Rico, H, Arnanz, F, Revilla, M et al. Total and regional bone mineral content in women treated with GnRH agonists. Calcif Tissue Int 1993; 52: 354–57.CrossRefGoogle ScholarPubMed
115Compston, JE, Yamaguchi, K, Croucher, PI, Garrahan, NJ, Lindsay, PC, Shaw, RW. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1994 (in press).CrossRefGoogle Scholar
116Riis, BJ, Christiansen, C, Johansen, JS, Jacobson, J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists. J Clin Endocrinol Metab 1990; 70: 920–24.CrossRefGoogle ScholarPubMed
117Eldred, JM, Haynes, PJ, Thomas, EJ. A randomised double-blind controlled trial of the effects on bone metabolism of the combination of naferelin acetate and norethisterone. Clin Endocrinol (Oxf) 1992; 37: 354–59.CrossRefGoogle Scholar
118Surrey, ES, Judd, HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotrophin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomised trial. J Clin Endocrinol Metab 1992; 75: 558–63.Google Scholar
119Lindsay, R, Hart, DM, Kraszewski, A. Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 1980; 280: 1207–209.CrossRefGoogle ScholarPubMed